Recent reforms to medical device registration in China are revamping how innovative products are approved for market entry. Collectively, these measures aim to reduce regulatory hurdles, enhance quality systems, encourage digital transformation, and promote international collaboration. This signals China’s ambition to move beyond low-end to mid-end device manufacturing and position itself as a global leader in high-end medical technologies.

Optimizing Regulation Across the Device Life Cycle

A key component of China’s recent strategy is the release of the Announcement on Optimizing Whole-Life-Cycle Regulation to Support Innovative Development of High-End Medical Devices in July 2025. This policy outlines ten strategic measures designed to improve regulatory efficiency while maintaining safety and quality standards, particularly for advanced technologies such as artificial intelligence (AI)-based diagnostics, surgical robots, and high-end imaging equipment.

This new policy is focused on streamlining the regulatory process while at the same time ensuring safety and high levels of quality for products created with cutting-edge technology. This regulation takes a comprehensive lifecycle approach, including pre-market classification processes, prior approval, post-market observations, and ongoing inspections of the devices. Another key component of this regulation is the adjustment of product classification systems in recognition of new technologies.

In addition, the NMPA has also committed to the acceleration of technical standards, thereby allowing innovators to know what to expect from a regulatory perspective and providing a foundation from which to build a new product.

Enabling Overseas Testing and Self-Inspection

In response to the numerous issues caused by China’s requirement for type testing to be conducted in China, which typically resulted in lengthy wait times for manufacturers seeking to get access to the market, the NMPA issued the “Guidelines for Self-inspection/Tests Verification of China Medical Device Registration” in September 2025, formally authorizing foreign Class II and Class III medical devices to be self-inspected and tested outside of China.

Although this regulatory amendment may shorten approval timelines for foreign Class II and Class III Devices, it will simultaneously impose strict requirements for the Quality Management System (QMS) of manufacturers, including the ability to maintain appropriately qualified inspection staff, to conduct self-inspections and tests in compliance with Good Manufacturing Practice (GMP) standards, and the use of overseas testing facilities that meet established standards. The change reflects the growing confidence of the Chinese government in its regulatory framework and its willingness to utilize international test data, provided that manufacturers have robust internal control and traceability systems.

Promoting International Collaboration

In addition to domestic reforms, China has engaged in efforts to collaborate with other countries through international regulatory systems and processes. China’s association with Malaysia and its successful launch of the Malaysia-China Medical Device Regulatory Reliance Program (Pilot Phase I) in July 2025 is an example of efforts to promote collaboration with foreign partners on regulatory issues.

This program is the first reciprocal arrangement established between Malaysia and China as part of the Global Harmonization Working Party (GHWP). The pilot phase I is focused on regulatory reliance for in vitro diagnostic (IVD) devices and has a limited scope.

As part of the program, IVDs that are approved for export by the Malaysian authority will have access to China’s “Green Channel”, and eligible Chinese products may use Malaysia’s verification pathway.

Positioning China in the Regional Innovation Landscape

China’s recent initiatives mirror a broader shift in Asia’s medical device landscape. As highlighted by parallel developments in Korea, where the government has established an extensive investment program targeting AI diagnostics, robotics, and advanced implants, Asian governments are increasingly seeking to move up the value chain in medical technology.

China stands out for the breadth and depth of its policy interventions. Beyond regulatory reforms, recent policies emphasize partnership between medical device companies and AI firms, subsidies for computing resources, and financial support for hospitals adopting AI technologies.

Conclusion

China’s 2025 policy measures reflect a clear strategic direction: supporting innovation while enhancing regulatory rigor and quality management. By optimizing life-cycle regulation, enabling self-testing overseas, and engaging in international regulatory cooperation, China is laying the foundation for sustained growth in its medical device industry.

For foreign manufacturers, these changes bring about both opportunities and challenges. Faster pathways and greater flexibility come with heightened focus on quality systems and compliance. More advanced Chinese medical devices will compete with Western-made advanced products all over the world.